Chronic GVHD, an autoimmune disease that follows allogeneic hematopoietic-cell
transplantation, is characterized by infections and debilitating tissue injury leading to …

Chronic graft versus host disease (GVHD) is a major cause of morbidity and mortality after
allogeneic hematopoietic cell transplantation. Clinically, chronic GVHD is a pleiotropic …

Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic
stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in …

Several international recommendations address the assessment of graft-versus-host
disease (GvHD) after hematopoietic cell transplantation (HCT). This position statement by …

With the increasing use of mismatched, unrelated, and granulocyte colony-stimulating factor–
mobilized peripheral blood stem cell donor grafts and successful treatment of older …

Abstract Approximately 35% to 50% of patients otherwise cured of hematologic
malignancies after allogeneic hematopoietic stem cell transplantation will develop the …

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is potentially curative for a
number of hematologic conditions, both malignant and nonmalignant. However, its success …

Purpose To identify diagnostic and prognostic markers of chronic graft-versus-host disease
(cGVHD), the major cause of morbidity and mortality after allogeneic hematopoietic cell …

Positive results from recent clinical trials have significantly expanded current therapeutic
options for patients with chronic graft-versus-host disease (GVHD). However, new insights …

Chronic graft‐versus‐host disease (cGvHD) remains the most important long‐term
complication of allogeneic hematopoietic cell transplantation (allo‐HCT), but the field has …